Alcon (ALC) Stock Price, News & Analysis

Company Overview

Alcon is a global leader in eye care, specializing in the development, manufacturing and distribution of surgical equipment and vision care products. The company operates through two primary business segments—Surgical and Vision Care—to serve the full spectrum of ophthalmic needs. Its Surgical business provides advanced technologies for cataract, vitreoretinal, refractive and glaucoma procedures, while its Vision Care division offers daily disposable and reusable contact lenses along with lens care solutions.

Within the Surgical segment, Alcon’s portfolio includes phacoemulsification systems, intraocular lenses and laser systems designed to enhance surgical precision and patient outcomes. The Vision Care segment features brands such as DAILIES®, PRECISION1® and TOTAL30® contact lenses, plus associated cleaning and disinfecting solutions. Alcon’s products reach ophthalmologists, optometrists and patients in over 140 countries, supported by regional manufacturing facilities, clinical training centers and a global sales force.

Originally founded in Fort Worth, Texas, in 1945 by Robert Alexander and William Conner, Alcon grew from a single storefront pharmacy into a standalone eye care company. Headquartered in Geneva, Switzerland, since its 2019 spin-off from Novartis, Alcon maintains research and development hubs in Europe, North America and Asia. Under the leadership of Chief Executive Officer David Endicott and Chief Financial Officer John P. Wiley, the company continues to invest in innovation aimed at improving vision health worldwide.

Key Stats

• Today's Range: $87.06 to $88.71
• 50-Day Range: $84.77 to $94.83
• 52-Week Range: $80.48 to $101.10
• Volume: 1.65 million shs
• Average Volume: 1.23 million shs
• Market Capitalization: $43.74 billion
• P/E Ratio: 39.41
• Dividend Yield: N/A
• Price Target: $106.13
• Consensus Rating: Moderate Buy

Alcon Stock Analysis - MarketRank™

Alcon scored higher than 55% of companies evaluated by MarketBeat, and ranked 483rd out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alcon has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alcon has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.58%

Earnings Growth

Earnings for Alcon are expected to grow by 8.58% in the coming year, from $3.03 to $3.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alcon is 39.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.38.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alcon is 39.41, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.32.

Price to Earnings Growth Ratio

Alcon has a PEG Ratio of 2.23. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Alcon has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.26% of the float of Alcon has been sold short.

Short Interest Ratio / Days to Cover

Alcon has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alcon has recently increased by 17.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

Alcon does not currently pay a dividend.

Dividend Growth

Alcon has only been increasing its dividend for 4 years.

Dividend Sustainability

Based on earnings estimates, Alcon will have a dividend payout ratio of 10.03% next year. This indicates that Alcon will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.26% of the float of Alcon has been sold short.

Short Interest Ratio / Days to Cover

Alcon has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alcon has recently increased by 17.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.37

News Sentiment

Alcon has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Alcon this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for ALC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alcon to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alcon insiders have not sold or bought any company stock.

Percentage Held by Institutions

53.86% of the stock of Alcon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALC Stock Analysis - Frequently Asked Questions

How have ALC shares performed this year?

Alcon's stock was trading at $84.89 at the beginning of 2025. Since then, ALC stock has increased by 4.5% and is now trading at $88.6810.

How were Alcon's earnings last quarter?

Alcon (NYSE:ALC) issued its quarterly earnings data on Tuesday, May, 13th. The healthcare company reported $0.73 EPS for the quarter, missing analysts' consensus estimates of $0.77 by $0.04. The firm's quarterly revenue was up .3% on a year-over-year basis.
Read the conference call transcript.

Is Alcon doing a stock buyback?

Alcon's board initiated a share repurchase program on Tuesday, February 25th 2025, which authorizes the company to buy back $750,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 1.7% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's management believes its stock is undervalued.

Does Alcon have any subsidiaries?

Alcon subsidiaries include these companies: Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.

Who are Alcon's major shareholders?

Top institutional investors of Alcon include Compagnie Lombard Odier SCmA (0.17%), Banque Pictet & Cie SA (0.11%), Canoe Financial LP (0.07%) and Ruffer LLP (0.06%).

How do I buy shares of Alcon?

Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alcon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alcon investors own include CocaCola (KO), AT&T (T), Walt Disney (DIS), PepsiCo (PEP), Verizon Communications (VZ), Cisco Systems (CSCO) and Johnson & Johnson (JNJ).

Company Calendar

• Last Earnings: 5/13/2025
• Record date for 5/15 Dividend: 5/14/2025
• Ex-Dividend for 5/15 Dividend: 5/14/2025
• Dividend Payable: 5/15/2025
• Today: 7/22/2025
• Next Earnings (Estimated): 8/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Facilities
• Current Symbol: NYSE:ALC
• CIK: 1167379
• Web: www.alcon.com
• Phone: 418172930450
• Fax: 41-58-911-3222
• Employees: 25,599
• Year Founded: 1945

Price Target and Rating

• Average Price Target for Alcon: $106.13
• High Price Target: $120.00
• Low Price Target: $84.00
• Potential Upside/Downside: +19.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.25
• Trailing P/E Ratio: 39.41
• Forward P/E Ratio: 29.27
• P/E Growth: 2.23
• Net Income: $1.02 billion
• Net Margins: 11.28%
• Pretax Margin: 13.45%
• Return on Equity: 6.95%
• Return on Assets: 4.92%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 2.70
• Quick Ratio: 1.66

Sales & Book Value

• Annual Sales: $9.91 billion
• Price / Sales: 4.41
• Cash Flow: $5.66 per share
• Price / Cash Flow: 15.68
• Book Value: $43.70 per share
• Price / Book: 2.03

Miscellaneous

• Outstanding Shares: 493,240,000
• Free Float: N/A
• Market Cap: $43.74 billion
• Optionable: Optionable
• Beta: 0.95